Sign In
Buy MBIO
$0.762
-0.0075 (-0.98%)
At Close: Jun 02, 2026
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution
08:30am, Thursday, 14'th May 2026
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- MindBio Therapeutics
IBN Announces Latest Episode of The TechMediaWire Podcast featuring Justin Hanka, CEO of MindBio Therapeutics Corp.
08:44am, Tuesday, 12'th May 2026
This news release has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising This news release has been disseminated on behalf of MindBio Therapeutics Corp. and may
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Leveraging AI, Voice Analysis to Develop Intoxication Detection
08:30am, Tuesday, 12'th May 2026
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- MindBio Therapeutics Corp
MindBio Announces Closing of Private Placement
03:45pm, Wednesday, 01'st Apr 2026
Vancouver, British Columbia – April 1, 2026 – TheNewswire - MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6); (OTCQB:MBQIF) (the “ Company ” or “ MindBio ”), a biotechnology
MindBio Announces Upsize to Private Placement up to $1.5 Million
08:05am, Thursday, 19'th Mar 2026
Vancouver, British Columbia – TheNewswire - March 19, 2026 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6); (OTCQB:MBQIF), (the “ Company ” or “ MindBio ”), a biotechno
Critical Contrast: Mustang Bio (NASDAQ:MBIO) & AstraZeneca (NASDAQ:AZN)
01:24am, Friday, 27'th Feb 2026
Mustang Bio (NASDAQ: MBIO - Get Free Report) and AstraZeneca (NASDAQ: AZN - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on
MindBio Announces Private Placement to Raise up to $650,000
09:15am, Wednesday, 18'th Feb 2026
Vancouver, British Columbia - TheNewswire - February 18, 2026 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6); (OTCQB:MBQIF), (the “ Company ” or “ MindBio ”), a biotechn
MindBio Advances Large-Scale Deployment of Voice Intoxication Detection Through Integrated Edge AI Hardware-Software Platform
08:05am, Wednesday, 18'th Feb 2026
Vancouver, British Columbia – TheNewswire - February 18, 2026 – MindBio Therapeutics Corp. (CSE: MBIO) (Frankfurt: WF6) (OTCQB: MBQIF) (“MindBio” or the “Company”) , a biotechnology compan
CSE Bulletin: Consolidation - MindBio Therapeutics Corp. (MBIO)
05:11pm, Tuesday, 04'th Nov 2025
Toronto, Ontario--(Newsfile Corp. - Le 4 novembre/November 2025) - MindBio Therapeutics Corp. has announced
Talisker Receives Assay Results from 1105 Level Lateral Development at the Mustang Mine
07:00am, Thursday, 24'th Jul 2025
TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX: TSK, OTCQX: TSKFF) is pleased to announce that the Company has received assay results fro
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy
11:41am, Tuesday, 08'th Jul 2025
Mustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.
Dow Dips 1%; Mustang Bio Shares Spike Higher
12:30pm, Monday, 07'th Jul 2025
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 400 points on Monday.
This BlackRock stock just spiked over 300%
11:51am, Monday, 07'th Jul 2025
Shares of Mustang Bio (NASDAQ: MBIO) surged on Monday as investors responded to a significant approval from the Food and Drug Administration (FDA).
In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
04:15pm, Wednesday, 05'th Mar 2025
WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (�
